Executive Summary (This is a document excerpt)

While the FDA opened the way for more pharmaceutical firm experimentation with radio frequency identification (RFID) tags, adoption beyond a handful of pilots among the top-50 pharma firms is unlikely until a stronger business case or meatier regulations emerge. Beyond lifting labeling restrictions, the FDA needs to encourage experimentation without hurting pharma's pocketbook by working toward standards and funding tag readers in the distribution chain.

Buy Risk-Free

Download and print PDF immediately. Price: US $499

Our Money-Back Guarantee: If you are not completely satisfied, return it for a full refund within three weeks of your online purchase.

Already a Forrester Client?
Log in to read this document.